ACE2 as therapy for glomerular disease: the devil is in the detail

Michael J. Ross, Masaomi Nangaku

Research output: Research - peer-reviewComment/debate

  • 1 Citations

Abstract

Angiotensin-converting enzyme 2 cleaves angiotensin (Ang) II to Ang(1-7), which antagonizes the deleterious effects of Ang II. In this issue, 2 groups administered angiotensin-converting enzyme 2 in murine models of kidney disease. Angiotensin-converting enzyme 2 did not improve glomerular injury in 2 models of mild diabetic nephropathy but was partially protective in an Alport syndrome model. These discrepant findings may be explained by the inability of angiotensin-converting enzyme 2 to reach the urinary space in the absence of severe proteinuria.

LanguageEnglish (US)
Pages1269-1271
Number of pages3
JournalKidney International
Volume91
Issue number6
DOIs
StatePublished - Jun 1 2017

Fingerprint

Therapeutics
angiotensin converting enzyme 2
Angiotensin II
Hereditary Nephritis
Kidney Diseases
Diabetic Nephropathies
Proteinuria
Wounds and Injuries
angiotensin I (1-7)

ASJC Scopus subject areas

  • Medicine(all)
  • Nephrology

Cite this

ACE2 as therapy for glomerular disease : the devil is in the detail. / Ross, Michael J.; Nangaku, Masaomi.

In: Kidney International, Vol. 91, No. 6, 01.06.2017, p. 1269-1271.

Research output: Research - peer-reviewComment/debate

@article{296afdc08c35443480f316e3a47b627e,
title = "ACE2 as therapy for glomerular disease: the devil is in the detail",
abstract = "Angiotensin-converting enzyme 2 cleaves angiotensin (Ang) II to Ang(1-7), which antagonizes the deleterious effects of Ang II. In this issue, 2 groups administered angiotensin-converting enzyme 2 in murine models of kidney disease. Angiotensin-converting enzyme 2 did not improve glomerular injury in 2 models of mild diabetic nephropathy but was partially protective in an Alport syndrome model. These discrepant findings may be explained by the inability of angiotensin-converting enzyme 2 to reach the urinary space in the absence of severe proteinuria.",
author = "Ross, {Michael J.} and Masaomi Nangaku",
year = "2017",
month = "6",
doi = "10.1016/j.kint.2017.04.001",
volume = "91",
pages = "1269--1271",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - ACE2 as therapy for glomerular disease

T2 - Kidney International

AU - Ross,Michael J.

AU - Nangaku,Masaomi

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Angiotensin-converting enzyme 2 cleaves angiotensin (Ang) II to Ang(1-7), which antagonizes the deleterious effects of Ang II. In this issue, 2 groups administered angiotensin-converting enzyme 2 in murine models of kidney disease. Angiotensin-converting enzyme 2 did not improve glomerular injury in 2 models of mild diabetic nephropathy but was partially protective in an Alport syndrome model. These discrepant findings may be explained by the inability of angiotensin-converting enzyme 2 to reach the urinary space in the absence of severe proteinuria.

AB - Angiotensin-converting enzyme 2 cleaves angiotensin (Ang) II to Ang(1-7), which antagonizes the deleterious effects of Ang II. In this issue, 2 groups administered angiotensin-converting enzyme 2 in murine models of kidney disease. Angiotensin-converting enzyme 2 did not improve glomerular injury in 2 models of mild diabetic nephropathy but was partially protective in an Alport syndrome model. These discrepant findings may be explained by the inability of angiotensin-converting enzyme 2 to reach the urinary space in the absence of severe proteinuria.

UR - http://www.scopus.com/inward/record.url?scp=85019112322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019112322&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2017.04.001

DO - 10.1016/j.kint.2017.04.001

M3 - Comment/debate

VL - 91

SP - 1269

EP - 1271

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 6

ER -